11/19 | Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. (opens in a new tab) The Journal of Immunology. November 6, 2019.
|
---|
6/19 | Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1. (opens in a new tab) Drug and Chemical Toxicology . June 10, 2019 .
|
---|
5/19 | Su1818 – Preclinical Efficacy and Safety of Nx-13: A Novel Nlrx1-Targeting Immunometabolic Therapeutic for Crohn’s Disease and Ulcerative Colitis. (opens in a new tab) AGA Journals . May 2019.
|
---|